(19)
(11) EP 2 234 639 A2

(12)

(88) Date of publication A3:
27.08.2009

(43) Date of publication:
06.10.2010 Bulletin 2010/40

(21) Application number: 08860961.5

(22) Date of filing: 15.12.2008
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
C12N 9/18(2006.01)
C12Q 1/44(2006.01)
C07K 16/40(2006.01)
C12N 15/11(2006.01)
(86) International application number:
PCT/EP2008/067493
(87) International publication number:
WO 2009/077479 (25.06.2009 Gazette 2009/26)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA MK RS

(30) Priority: 17.12.2007 US 14275 P

(71) Applicant: Novartis AG
4056 Basel (CH)

(72) Inventors:
  • PAIGEN, Beverly
    Bar Harbor, Maine 04609 (US)
  • STYLIANO, Ioannis, M.
    Philadelphia, PA 19104 (US)
  • WANG, Xiaosong
    Belmont, MA 02478 (US)

(74) Representative: Vögeli-Lange, Regina 
Novartis Pharma AG Patent Department
4002 Basel
4002 Basel (CH)

   


(54) ALTERING HIGH-DENSITY LIPOPROTEIN LEVELS THROUGH CARBOXYLESTERASE 1 MODULATION